Q1 2025 Arcutis Biotherapeutics Inc Earnings Call Transcript
Key Points
- Arcutis Biotherapeutics Inc (ARQT) reported a significant year-over-year revenue growth of 196% for Q1 2025, reaching $63.8 million.
- The company achieved a 10% increase in prescription demand compared to Q4 2024, despite typical Q1 headwinds.
- ZORYVE's insurance coverage is robust, with approximately 80% of prescriptions being reimbursed.
- The company anticipates further growth with upcoming approvals for ZORYVE foam for scalp and body psoriasis and ZORYVE cream for atopic dermatitis in young children.
- Arcutis Biotherapeutics Inc (ARQT) is seeing a shift in the market from topical steroids to non-steroidal treatments, positioning ZORYVE as a leading option.
- Despite strong performance, Q1 revenues were slightly down by 2% compared to Q4 2024 due to typical first-quarter deductible resets and insurance changes.
- SG&A expenses increased by 17% year-over-year, reflecting higher promotional spending for current and upcoming launches.
- The company faces challenges in expanding ZORYVE's adoption in primary care, requiring more frequent engagements to build familiarity.
- There is uncertainty regarding the ongoing patent litigation with Padagis, although the stay provides temporary relief.
- The company anticipates some seasonality impact on ZORYVE's performance, particularly in the summer months.
Good day, and welcome to Arcutis Biotherapeutics 2025 first-quarter financial results conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the call over to Amanda Sheldon. Please go ahead.
Thank you, Heidi. Good afternoon, everyone, and thank you for joining us today to review our first quarter 2025 financial results and business update. Slides for today's call are available on the Investors section of the Arcutis website. On the call today are Frank Watanabe, President and CEO; Patrick Burnett, Chief Medical Officer; Todd Edwards, Chief Commercial Officer; and Latha Vairavan, Chief Financial Officer. I would like to remind everyone that we will be making forward-looking statements during this call.
These statements are subject to certain risks and uncertainties, and our actual results may differ. We encourage you to review all of the company's filings with the Securities and Exchange Commission,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
